Minerva Imaging announces the appointment of Dr. Ian Wilson as Head of Partnering & Business Strategy. In this role, Ian will support Minerva’s continued expansion as a partner of choice for pharma and biotech companies developing cutting‑edge radiopharmaceuticals and molecular imaging solutions.

Ian Wilson is an experienced biotech leader with more than 30 years in radiopharmaceuticals and in vivo medical diagnostics, having held senior executive roles across both global corporations and venture‑backed start‑ups, including ImaginAb, Xstrahl and GE HealthCare. In his previous positions, Ian focused on imaging and radiotherapy technologies and agents, and worked closely in partnership with Pharmaceutical Biotech companies and Academic institutes to advance the availability of these agents.

“Ian’s appointment is aligned with our continued strategy to increase Minerva’s growth in targeted radionuclide therapies, translational imaging, and global partnerships,” said Carsten Nielsen, Chief Executive Officer of Minerva Imaging. “Ian has a track record of establishing meaningful strategic partnerships regarding radiopharmaceutical innovation and commercialization, which will benefit Minerva’s clients and pipeline.”

Commenting on his appointment, Ian Wilson said: “I am looking forward to working with Minerva’s teams in Denmark and globally and supporting the company’s vision to advance novel radiopharmaceuticals from discovery through clinical development, which reflects my own long‑standing commitment to leveraging advanced imaging and radiotherapeutic technologies to improve outcomes for patients with cancer and other serious diseases”.

Founded in 2011 and headquartered in Ølstykke, Denmark, Minerva Imaging employs a highly skilled team and delivers integrated services across preclinical and clinical development, with core expertise in oncology, cardiovascular disease, and in vivo molecular imaging. The company engages closely with clients to shape translational strategies, combining advanced animal models, radiopharmaceutical development, and GMP‑oriented capabilities to accelerate and de‑risk drug development programs.

Ian Wilson

About Minerva Imaging

Minerva Imaging is a fully integrated CRO and CDMO specialised in targeted radionuclide therapies. The company focuses on the use of advanced models within oncology, cardiovascular diseases and in vivo molecular imaging for translational research and drug development. Minerva Imaging engages with its clients to understand their scientific questions and discuss how its methods and capabilities can provide answers. The facility located in Denmark offers best–in–industry fully integrated radiopharmaceutical research, drug development, and manufacturing services. Minerva’s competences are built on over 25 years of research within oncology and molecular imaging performed at the University of Copenhagen and Rigshospitalet, the National University Hospital of Denmark. 

Follow us on LinkedIn for the latest news updates or visit minervaimaging.com for more information.